Bio-Analytical Method Development and Validation for Estimation of Ertugliflozin by RP-HPLC in Dosage Form.
International Journal of Drug Delivery Technology · 16.04.2026 · 16 (14s)
DOI: 10.25258/ijddt.16.14s.30 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 16.04.2026. Verfasst von Priyanka Balasaheb Kedar und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Ertugliflozin is an antidiabetic medication that belongs to the class of Sodium-Glucose Cotransporter2 inhibitors. Ertugliflozin is mainly employed to reduce elevated blood glucose levels.
Objective
The aim of the current study is to establish a reliable, precise, and validated bioanalytical method for quantifying Ertugliflozin in human plasma using reverse-phase high-performance liquid chromatography. Materials & Methods: Chromatographic analysis was performed at 239 nm on a Thermo C18 column (150 mm × 4.6 mm, 5 μm) using an optimized method. The flow rate was 0.9 mL/min, using a methanol:0.1 % GAA (75:25% v/v) mixture at pH 3, with 1 mL of plasma as the mobile phase. The method underwent validation for its linearity, accuracy, precision, and robustness, following the standards outlined in the ICH guidelines. The validated method was then used to determine the marketed formulation in plasma.
Results
Among six trials, the optimized method showed a sharp peak. Chromatographic parameters included a retention time of 3.872 minutes, 5931 theoretical plates, a tailing factor of 0.94, and a resolution of 2.5. A linear response was observed over the concentration range of 2 to 10 µg/ml, with a correlation coefficient of 0.9992, indicating excellent linearity. Recovery studies at three concentration levels showed 99.39% at 80%, 99.25% at 100%, and 99.58% at 120%, all with RSD less than 2%. This indicated good accuracy. LOD and LOQ were 2.1782 μg/mL and 0.7188 µg/mL, respectively. The estimation of EFG in the marketed formulation was 99.25%.
Conclusion
The developed RP-HPLC method was validated and is suitable for routine quantification of drugs in biological samples
Zitieren
APA
Kedar, P. B., Gaware, V. M., Kunde, V. D., Gaikar, M. T., & Dhamak, K. B. (2026). Bio-Analytical Method Development and Validation for Estimation of Ertugliflozin by RP-HPLC in Dosage Form. International Journal of Drug Delivery Technology, 16(14s). https://doi.org/10.25258/ijddt.16.14s.30
Vancouver
Kedar PB, Gaware VM, Kunde VD, Gaikar MT, Dhamak KB. Bio-Analytical Method Development and Validation for Estimation of Ertugliflozin by RP-HPLC in Dosage Form. International Journal of Drug Delivery Technology. 2026;16(14s). doi:10.25258/ijddt.16.14s.30
BibTeX
@article{Kedar2026,
author = {Kedar, Priyanka Balasaheb and Gaware, Vinayak Madhukar and Kunde, Vikas Damu and Gaikar, Mayur Trimbak and Dhamak, Kiran Bhausaheb},
title = {Bio-Analytical Method Development and Validation for Estimation of Ertugliflozin by RP-HPLC in Dosage Form},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {14s},
doi = {10.25258/ijddt.16.14s.30}
}
EUVIMED